Biography

Dr Atallah is the Associate Dean for Clinical Affairs at Dubai Medical University. Prior to joining DMU he served as Cardiovascular Senior Pharmacotherapy Specialist at Cleveland Clinic Abu Dhabi and Clinical Associate Professor at Cleveland Clinic Lerner College of Medicine. Prior to joining Cleveland Clinic he was on faculty as Assistant Professor of Clinical Pharmacy at King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) in Riyadh.

Dr. Atallah received his PharmD from Bernard J. Dunn School of Pharmacy in Virginia and completed an ASHP accredited post graduate residency at Winchester Medical Center in Virginia. He was awarded the “Graduate of the Last Decade” award by his alma mater. Dr. Atallah is board certified in pharmacotherapy with added qualifications in Cardiology. He also holds an advanced antithrombotic management certificate from ASHP. Dr Atallah is a fellow of the Heart Failure Society of America (HFSA) and the American College of Clinical Pharmacy (ACCP). He has several publications and presentations at national and international conferences. He was awarded the 2021 ACCP Cardiology PRN international award. His research interests are in various aspects of cardiovascular pharmacotherapy with focus on antithrombotic therapy, heart failure and hyperlipidemia.

Back

Education

• Bachelor of Science in Biology, American University of Beirut, Lebanon (2003-2006)
• Master of Science in Biology, Fairleigh Dickinson University, New Jersey, USA (2006-2008)
• Doctor of Pharmacy, Shenandoah University, Bernard J Dunn School of Pharmacy, Virginia, USA (2008-2012)
• ASHP-Accredited PGY-1 Pharmacy Practice Residency, Winchester Medical Center, Virginia, USA (2012-2013)
• Teaching Certificate, Shenandoah University, Virginia, USA (2012-2013)
• Advanced Antithrombotic Traineeship, ASHP Foundation, USA (2016-2017)

Back

Research Interests

• Cardiovascular pharmacotherapy
• Pharmacist-led initiatives
• Clinical outcomes

Back

Research Publications

• Bader F, Atallah B, Brennan LF, Rimawi RH, Khalil ME. Heart failure in the elderly: ten peculiar management considerations. Heart Fail Rev. 2017; 22(2):219-228.
  
• Atallah B, Bader F, El Lababidi R. Pharmacotherapy consideration post heart transplantation: What general cardiologists should know? Cardiology Today. November, 2017.
  
• Bader F, Atallah B, Sadik ZG, Tbishat L, Gabra G, Soliman M, Bakr K, Ferrer R, Stapleton J, Khalil M. Nurse-led education for heart failure patients in developing countries. Br J Nurs. 2018 Jun 28; 27(12):690-696.
  
• Bader F, Atallah B, Rizk J, AlHabbeb W. Heart transplantation in the middle east gulf region. Transplantation. 2018 Jul; 102(7):1023-1026
  
• Atallah B, Sadik ZG, Hisham M, et al. A per-protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region. ESC Heart Fail. 2019; 6(4):758-763
  
• Atallah, B, Sadik, ZG, Osoble, AA, et al. Establishing the first pharmacist‐led heart failure medication optimization clinic in the Middle East Gulf Region. J Am Coll Clin Pharm. 2020; 3: 877– 884.
  
• Atallah B, Khaddage R, Sadik ZG, et al. Lipid Control Post Coronary Artery Bypass Graft: One Year Follow-Up of a Middle-Eastern Cohort. Global Heart. 2020; 15(1): 12.
  
• Bader F, Mallah S, Atallah B. Choosing the best antithrombotic regimen in patients with ventricular assist devices. Curr Opin Cardiol. 2020 Mar;35(2):162-169.
  
• Mallah SI, Atallah B, Moustafa F, Naguib M, El Hajj S, Bader F, Mehra MR. Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy. Prog Cardiovasc Dis. 2020 May-Jun;63(3):194-209. doi: 10.1016/j.pcad.2020.03.007
  
• Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):260-261. doi: 10.1093/ehjcvp/pvaa036.
  
• Atallah B, Mallah SI, AbdelWareth L, AlMahmeed W, Fonarow GC.   A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels Be Monitored in COVID-19 Patients? Eur Heart J Qual Care Clin Outcomes. 2020 Jul 1;6(3):204-207. doi: 10.1093/ehjqcco/qcaa033.
  
• Badreldin HA, Atallah B. Global Drug Shortages Due to COVID-19: Impact on Patient Care and Mitigation Strategies. Res Social Adm Pharm. 2021 Jan;17(1):1946-1949. doi: 10.1016/j.sapharm.2020.05.017.
  
• Bader F, Manla Y, Atallah B, Starling RC. Heart failure and COVID-19. Heart Fail Rev. 2021 Jan;26(1):1-10. doi: 10.1007/s10741-020-10008-2. PMID: 32720082;
  
• Atallah B, Sadik ZG, Salem N, El Nekidy WS, Almahmeed W, Park WM, Cherfan A, Hamed F, Mallat J. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia. 2021 Mar;76(3):327-335. doi: 10.1111/anae.15300.
  
• Salem N, Atallah B, El Nekidy WS, Sadik ZG, Park WM, Mallat J. Thromboelastography findings in critically ill COVID-19 patients. J Thromb Thrombolysis. 2021 May;51(4):961-965. doi: 10.1007/s11239-020-02300-7.
  
• Anouassi Z, Atallah B, Alsoud LO, El Nekidy W, Al Mahmeed W, AlJaabari M, Almuti K. Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region. J Cardiovasc Pharmacol. 2021 Feb 1;77(2):182-188. doi: 10.1097/FJC.0000000000000913.
  
• Atallah B, El Lababidi R, Jesse W, Noor L, Al Mahmeed W. Adapting to the COVID‑19 Pandemic at a Quaternary Care Hospital in the Middle East Gulf Region. Heart Views. 2020; 21(3):133-140.
• Göbölös L, Rácz I, Hogan M, Remsey-Semmelweis E, Atallah B, AlMahmeed W, AlSindi F, Suri RM, Bhatnagar G, Tuzcu EM. The role of renin-angiotensin system activated phagocytes in the SARS-CoV-2 coronavirus infection. J Vasc Surg. 2021 Jun;73(6):1889-1897. doi: 10.1016/j.jvs.2020.12.056.
  
• Atallah B, Hamour I, Mallah SI, Bonilla MF, Bader F. Traveling for heart transplantation and returning with COVID-19: a logistical, clinical, and pharmacotherapeutic challenge from the Middle East. Drugs Ther Perspect. 2021;37(1):29-34. doi: 10.1007/s40267-020-00792-0.
  
• Atallah B, AlMahmeed W. The Emirates Cardiac Society Congress 2020. Eur Heart J. 2021 Feb 21;42(8):807-809. doi: 10.1093/eurheartj/ehaa981.
  
• Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, Sefen JAN, Sidhu P, Atallah B, El-Lababidi R, Al-Qahtani M. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021 May 18;20(1):35. doi: 10.1186/s12941-021-00438-7.
  
• Alhabib KF, Al-Rasadi K, Almigbal TH, Batais MA, Al-Zakwani I, Al-Allaf FA, Al-Waili K, Zadjali F, Alghamdi M, Alnouri F, Awan Z, Kinsara AJ, AlQudaimi A, Almahmeed W, Sabbour H, Traina M, Atallah B, Al-Jarallah M, AlSarraf A, AlSayed N, Amin H,
• Altaradi H. Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry. PLoS One. 2021 Jun 4;16(6):e0251560. doi: 10.1371/journal.pone.0251560.
  
• El Nekidy WS, Almuti K, ElRefaei H, Atallah B, Mohammad LM, AlMahmeed W, Badr M, Abdallah K, Hamed F, Mallat J. QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484211069479. doi: 10.1177/10742484211069479.
  
• Hisham M, Ghalib HH, Kakar V, Kumar GP, Bader F, Atallah B. Anticoagulation practices and complications associated with Impella® support at an advanced cardiac center in the Middle East gulf region. J Thromb Thrombolysis. 2023 Jul;56(1):164-174. doi: 10.1007/s11239-023-02807-9. 
  
• Abidi E, El Nekidy WS, Atallah B, Al Zaman K, Ghisulal P, El Lababidi R, Manla Y, Ahmed I, Sadik Z, Taha A, Askalany M, Cherfan A, Helal M, Sultan S, Khan U, Kakar V, Mallat J. Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs. J Clin Med. 2023 May 29;12(11):3748. doi: 10.3390/jcm12113748.
  
• Alsalama, F, Alzaabi S, Salloum C, Abi Younes M, Bader F, Ghalib H, Atallah B. Ventricular arrhythmias, antiarrhythmic therapy and thyroidal illness in advanced heart failure: a case report and review of the literature. Drugs Ther Perspect 39, 147–155 (2023). https://doi.org/10.1007/s40267-023-00985-3
  
• Anouassi Z, Abril C, Ismail G, El Nekidy WS, Al-Hadeethi A, Bafadel A, Atallah B. A Case of Hemorrhagic Cholecystitis in a Patient on Apixaban After COVID-19 Infection. Am J Case Rep. 2023 Jul 21;24:e939677. doi: 10.12659/AJCR.939677.
  El Nekidy W, Abidi E, Nabil S, Kendakji S, Ali M, Aburuz S, Atallah, B, Hijazi F, Mallat J, Akour A. The Safety and Effectiveness of Apixaban in Patients with End-Stage Kidney Disease on Dialysis: A Retrospective Observational Study. J. Clin. Med. 2024, 13, 1351
  
• Saleh J,  El Nekidy W, Hisham M, Elrefaei H, Abidi E, Altakruri M, Kalagieh O, Alzaabi S, Atallah B, Chehab O, Ismail R, Sultan S. Impact of pharmacist-led transitions of care model on length of hospital stay and 30-day readmission rates at a quaternary care hospital: A pilot stud. JAPhA Practice Innovations. 2024, 1, https://doi.org/10.1016/j.japhpi.2024.100015
  
• Atallah, B, Ghalib, H. Pooling the NT-proBNP Benefits of ARNI: Fret the Index Hospitalization No More∗ . JACC. 2024 Mar, 83 (12) 1133–1135. https://doi.org/10.1016/j.jacc.2024.02.001
  
• Al Bitar M, Shantouf R, Al Azzoni A, Al Mahmeed W, Atallah B. Ischemia with no obstructed coronary arteries and microvascular testing procedures: a review of utility, pharmacotherapy, and current challenges. Front Cardiovasc Med. 2025 Feb 18;12:1523352. doi: 10.3389/fcvm.2025.1523352.
  
• Fiuzat M, Atallah B, Page R, Vardeny O. The Current Landscape of Training, Practice, and Roles of Pharmacists in the Field of Heart Failure. JACC Heart Fail. 2025 Jul 1;13(8):102551. doi: 10.1016/j.jchf.2025.102551. Epub ahead of print. PMID: 40602176.

External Profiles